

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following toxicities was most commonly observed with the addition of zolbetuximab to chemotherapy for patients with previously untreated HER2-negative advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma in the Phase III clinical investigation?
 - a. Ocular
 - b. Neurologic
 - c. Hematologic
 - d. Gastrointestinal
2. Which of the following proteins is targeted by zolbetuximab?
 - a. CLDN18.2
 - b. FGFR2
 - c. HER2
 - d. TROP2
3. Which of the following patients with advanced GEJ adenocarcinoma experienced the best numeric progression-free survival benefit with ramucirumab/FOLFIRI in the Phase II/III RAMIRIS trial?
 - a. All comers
 - b. Patients who had not previously received a taxane
 - c. Patients who had previously received a taxane
4. The bispecific antibody zanidatamab binds to which of the following?
 - a. Two distinct HER2 domains
 - b. HER2 and CD38
 - c. CD8 and CLDN18.2
 - d. HER2 and FGFR2b
5. Tislelizumab binds to which of the following proteins?
 - a. PD-1
 - b. HER3
 - c. CLDN18.2
 - d. TROP2